Radiolabeling of new generation magnetic poly(HEMA-MAPA) nanoparticles with 131I and preliminary investigation of its radiopharmaceutical potential using albino Wistar rats

Basit Öğe Kaydı
dc.contributor.authorAvcibaşi U.
dc.contributor.authorDemiroglu H.
dc.contributor.authorEdiz M.
dc.contributor.authorAkalin H.A.
dc.contributor.authorÖzçalişkan E.
dc.contributor.authorŞenay H.
dc.contributor.authorTürkcan C.
dc.contributor.authorÖzcan Y.
dc.contributor.authorAkgöl S.
dc.contributor.authorAvcibaşi N.
dc.date.accessioned2019-10-27T08:23:06Z
dc.date.available2019-10-27T08:23:06Z
dc.date.issued2013
dc.departmentEge Üniversitesien_US
dc.description.abstractIn this study, N-methacryloyl-l-phenylalanine (MAPA) containing poly(2-hydroxyethylmethacrylate) (HEMA)-based magnetic poly(HEMA-MAPA) nanobeads [mag-poly(HEMA-MAPA)] were radiolabeled with 131I [ 131I-mag-poly(HEMA-MAPA)], and the radiopharmaceutical potential of 131I-mag-poly(HEMA-MAPA) was investigated. Quality control studies were carried out by radiochromatographic method to be sure that 131I binded to mag-poly(HEMA-MAPA) efficiently. In this sense, binding yield of 131I-mag-poly(HEMA-MAPA) was found to be about 95-100%. In addition to this, optimum radiodination conditions for 131I-mag-poly(HEMA- MAPA) were determined by thin-layer radiochromatography studies. In addition to thin-layer radiochromatography studies, lipophilicity (partition coefficient) and stability studies for 131I-mag-poly(HEMA-MAPA) were realized. It was determined that lipophilicities of mag-poly(HEMA-MAPA) and 131I-mag-poly(HEMA-MAPA) were 0.12 ± 0.01 and 1.79 ± 0.76 according to ACD/logP algorithm program, respectively. Stability of the radiolabeled compound was investigated in time intervals given as 0, 30, 60, 180, and 1440 min. It was found that 131I-mag-poly(HEMA-MAPA) existed as a stable complex in rat serum within 60 min. After that, biodistribution and scintigraphy studies were carried out by using albino Wistar rats. It was determined that the most important 131I activity uptake was observed in the breast, the ovary, and the pancreas. Scintigraphy studies well supported biodistribution results. Copyright © 2013 John Wiley & Sons, Ltd.en_US
dc.identifier.doi10.1002/jlcr.3108en_US
dc.identifier.endpage716en_US
dc.identifier.issn0362-4803
dc.identifier.issue14en_US
dc.identifier.pmid24339009en_US
dc.identifier.scopusqualityQ2en_US
dc.identifier.startpage708en_US
dc.identifier.urihttps://doi.org/10.1002/jlcr.3108
dc.identifier.urihttps://hdl.handle.net/11454/26369
dc.identifier.volume56en_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.relation.ispartofJournal of Labelled Compounds and Radiopharmaceuticalsen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subject131Ien_US
dc.subjectdrug carrier systemsen_US
dc.subjectnanobeadsen_US
dc.subjectpoly(HEMA)en_US
dc.subjectpoly(HEMA-MAPA)en_US
dc.titleRadiolabeling of new generation magnetic poly(HEMA-MAPA) nanoparticles with 131I and preliminary investigation of its radiopharmaceutical potential using albino Wistar ratsen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

Scopus İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu